2018: Eurostars Granted Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” – MODIFY-NKRead more >
2018: Momentum continues to build in advance of Glycostem’s pivotal 2019 trials.Read more >
2018: Glycostem expands management team in expansion phase.Read more >
Company now occupies new 500-square-meter space at Pivot Park.
April 20, 2016
On the 20th of April 2016, the FDA Office of Orphan Products Development has granted orphan drug designation to Glycostem's NK Cell Product oNKord® for treatment of acute myeloid leukemia (AML)
Glycostem is delighted that we have been listed as the only not-public listed company in this article. If you are interested in the NK cell space, this is a recommended read.
New home for Glycostem's R&DRead more >
On the 2nd December Glycostem has officially launched its new website, which provides a comprehensive overview of our current position and ambitious plans on the application of NK cell immunotherapy in the treatment of cancer.Read more >
ODD for NK Cell Product oNKord® to treat AMLRead more >